Search Results
Your search for ,dUe matches 5408 pages
Showing 351 - 400
De Novo Metastatic Hormone-Sensitive Prostate Cancer
This is Part 2 of Novel Hormonal Therapies for Prostate Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Alicia K. Morgans, Neeraj Agarwal, and David VanderWeele discuss the management of de novo metastatic...
Biochemical Recurrence of Prostate Cancer
This is Part 1 of Novel Hormonal Therapies for Prostate Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Alicia K. Morgans, Neeraj Agarwal, and David VanderWeele discuss biochemical recurrence in prostate cancer. The...
Association of Delayed or Foregone Care Among Patients With Cancer and Patient-Clinician Identity Discordance
In a study reported in a research letter in JAMA Oncology, Patel et al found that delayed or foregone care due to patient-clinician discordance of identity (eg, race, religion, gender) was more common among patients with cancer vs noncancer controls. Approximately one-quarter of younger patients...
Sugemalimab in Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma
In a Chinese phase II study (GEMSTONE-201) reported in the Journal of Clinical Oncology, Huang et al found that the PD-L1 inhibitor sugemalimab produced durable responses in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma. Study Details In the multicenter trial, 78...
Tumor Genomic Profile and Risk for Arterial Thromboembolism in Patients With Solid Cancers
In a single-institution study reported in JACC: CardioOncology, Feldman et al found that somatic KRAS and STK11 alterations were associated with increased risk of arterial thromboembolism in patients with solid tumors, irrespective of tumor type. Study Details The retrospective cohort study used...
Immune Checkpoint Inhibition and Long-Term Survival in Patients With Metastatic Urothelial Cancer
In an analysis reported in JAMA Network Open, Zhu et al found that immune checkpoint inhibitor treatment did not appear to be associated with long-term survival in patients with metastatic urothelial cancer. Study Details The analysis included data from six trials of pembrolizumab, avelumab, and...
Bispecific Antibody REGN5459 Shows Activity in Patients With Relapsed or Refractory Multiple Myeloma
Although the 5-year relative survival rate for multiple myeloma is improving—up from 34.6% in 1998 to 53.9% in 2016—due to the approval of more effective therapies, multiple myeloma remains incurable, and new treatment options are needed, especially in the relapsed/refractory setting. A small phase ...
Study Finds Lung Cancer Incidence Rates Vary Significantly Among Florida’s Black and Hispanic Ethnic Subgroups
An analysis of lung cancer incidence rates showed wide variations among the racial and ethnic subgroups in Florida’s Black and Hispanic population, according to data presented by Cranford et al at the American Association for Cancer Research (AACR) Annual Meeting 2023 (Abstract 1902/8). Study...
IMbrave050: Recurrence-Free Survival With Adjuvant Atezolizumab Plus Bevacizumab for HCC
Adjuvant therapy with atezolizumab and bevacizumab improved recurrence-free survival in patients with hepatocellular carcinoma (HCC) following surgical resection or ablation, according to results from the phase III IMbrave050 clinical trial, which were presented by Chow et al at the American...
Pathologic Complete Response and Outcomes in Localized Soft-Tissue Sarcoma Treated With Neoadjuvant Chemoradiotherapy or Radiotherapy
In an analysis reported in JAMA Oncology, Wang et al found that pathologic complete response (pCR) was associated with improved outcomes among patients with localized soft-tissue sarcoma receiving neoadjuvant chemoradiotherapy or radiotherapy. The analysis included data from patients from two RTOG...
Statewide Survey May Provide Insight Into Cancer-Related Knowledge, Beliefs, and Behaviors of Hispanic Individuals in Indiana
A new survey of Hispanic adults residing in Indiana may present a snapshot of their cancer-related knowledge, beliefs, and behaviors and provide guidance for the future development of tailored cancer screening messaging and prevention strategies, according to a study published by Espinoza-Gutarra...
Financial Toxicity of Cancer May Impact Partner’s Quality of Life
Researchers have discovered that the financial impact of an individual’s cancer diagnosis may also impact a partner’s health-related quality of life, according to a new study published by Ghazal et al in JAMA Network Open. “When you think of key developmental milestones young adults expect to...
Study Finds Precursor Pancreatic Lesions Occur Frequently in Healthy Human Pancreases
Pancreatic cancer is a rare disease, accounting for about 3% of all cancers in the United States. It is the deadliest of all solid malignancies, accounting for about 7% of all cancer deaths each year, and carries a 5-year survival rate of just 11.5%. According to the American Cancer Society, in...
Endoscopic Surveillance in Patients at Risk for Hereditary Diffuse Gastric Cancer
In a prospective cohort study reported in The Lancet Oncology, Asif et al found that endoscopic surveillance may be an alternative to prophylactic total gastrectomy in patients at risk for hereditary diffuse gastric cancer due to germline CDH1 pathogenic variants. Study Details In the study, 270...
Interaction of H pylori Infection and Germline Pathogenic Variants in Risk for Gastric Cancer
In a Japanese study reported in The New England Journal of Medicine, Usui et al found that Helicobacter pylori infection affected the risk of gastric cancer in patients with predisposing germline pathogenic variants, including variants in homologous recombination genes. As stated by the...
Healthy Lifestyles May Be Associated With Reduced Mortality Risk in Pediatric Cancer Survivors
Researchers have provided strong evidence that a healthy lifestyle may significantly reduce mortality in adults who have survived pediatric cancer, according to a new study published by Dixon et al in The Lancet. The findings are among the first to reveal that the specific primary causes of...
Neoadjuvant Pembrolizumab in Desmoplastic Melanoma
Neoadjuvant pembrolizumab may significantly improve the management of desmoplastic melanoma, increasing the likelihood of successful resection and reducing the need for further surgery or radiation therapy, according to the response data presented at the 2022 ASCO Annual Meeting, with the surgical...
Interferon Alfa-2b May Substantially Increase Survival in Patients With Lymphomatoid Granulomatosis
Researchers have demonstrated that patients with low-grade lymphomatoid granulomatosis who were treated with the immunotherapy interferon alfa-2b may survive for a median of 20 years after diagnosis, according to a novel study published by Melani et al in The Lancet Haematology. The findings...
Risk of Local Recurrence After Breast-Conserving Therapy in Patients With Multiple Ipsilateral Breast Cancer
In a phase II trial (ACOSOG Z11102/Alliance) reported in the Journal of Clinical Oncology, Judy C. Boughey, MD, and colleagues found that breast-conserving therapy was associated with a low rate of local recurrence in women with multiple ipsilateral breast cancer sites. Study Details A total of 204 ...
ChatGPT May Have Potential to Help Educate Patients With Cirrhosis and Hepatic Cancer in Basic Knowledge, Lifestyle, and Treatment Domains
Investigators revealed that the artificial intelligence (AI) chatbot ChatGPT may help improve health outcomes for patients with cirrhosis and hepatic cancer by providing easy-to-understand information about basic knowledge, lifestyle modifications, and treatment options for these conditions,...
ELCC 2023: New Data on Amivantamab-vmjw in Patients With Advanced NSCLC and EGFR Exon 20 Insertion Mutations
New long-term data from the CHRYSALIS study evaluating amivantamab-vmjw in patients with advanced non–small cell lung cancer (NSCLC) and EGFR exon 20 insertion mutations whose disease progressed on prior platinum-based chemotherapy were presented by Lopez et al at the 2023 European Lung Cancer...
Nivolumab Injected Directly Into Spinal Fluid May Be Safe and Effective for Some Patients With Melanoma Who Have Leptomeningeal Disease
Researchers have found that a novel approach to administer intrathecal and intravenous nivolumab has proven safe and improved survival in a subset of patients who developed leptomeningeal disease from metastatic melanoma, according to a new study published by Glitza Olivia et al in Nature ...
RUBY Trial: Dostarlimab Plus Carboplatin and Paclitaxel in Advanced Endometrial Cancer
Adding immunotherapy to standard chemotherapy for the first-line treatment of advanced or the first recurrence of endometrial cancer significantly improved progression-free survival compared to chemotherapy alone, according to data presented by Mansoor Raza Mirza, MD, and colleagues at the March...
FDA Issues Draft Guidance Aimed at Improving Oncology Clinical Trials for Accelerated Approval
On March 24, the U.S. Food and Drug Administration (FDA) issued draft guidance, Clinical Trial Considerations to Support Accelerated Approval of Oncology Therapeutics, regarding clinical trial design considerations to support accelerated approval applications. The accelerated approval pathway is...
2024 ACA Proposal Aims to Reduce Health-Care Coverage Gaps
ASCO submitted comments in response to the Centers for Medicare & Medicaid Services’ (CMS) Patient Protection and Affordable Care Act 2024 Notice of Benefit and Payment Parameters proposed rule. ASCO’s comments support proposals aimed at reducing or eliminating gaps in health-care coverage, and ...
TALAPRO-2: Talazoparib Plus Enzalutamide Extends Radiographic Progression–Free Survival in Metastatic Castration-Resistant Prostate Cancer
The addition of the poly (ADP ribose) polymerase (PARP) inhibitor talazoparib to the androgen receptor signaling inhibitor enzalutamide achieved a statistically significant and clinically meaningful improvement in radiographic progression–free survival compared with placebo plus enzalutamide as...
ACCC Releases Advocacy Agenda at 49th Annual Meeting & Cancer Center Business Summit
The Association of Community Cancer Centers (ACCC) represents members nationwide from all care delivery settings. ACCC’s 49th Annual Meeting & Cancer Business Summit was held March 8–10, 2023, in Washington, DC, where the society released its advocacy agenda for 2023. Areas of Focus ACCC...
BRAF V600E–Mutated Colon Cancer
This is Part 2 of The Evolving Targeted Treatment Landscape for Colorectal Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. John Strickler, Stacey A. Cohen, and Harshabad Singh discuss the management of BRAF...
Axitinib and Avelumab in Recurrent/Metastatic Adenoid Cystic Carcinoma
In a single-center phase II trial reported in the Journal of Clinical Oncology, Renata Ferrarotto, MD, and colleagues found that the combination of axitinib and avelumab showed evidence of activity in patients with recurrent or metastatic adenoid cystic carcinoma. Study Details In the study, 28...
Large Study Finds Digital Breast Tomosynthesis May Be Superior to Digital Mammography for Breast Cancer Detection
In a study of over a million patients, digital breast tomosynthesis (DBT) showed improved breast cancer screening outcomes over screening with standard digital mammography alone. The results were published by Conant et al in Radiology. Breast cancer screening with two-dimensional (2D) digital...
FDA Issues Safety Communication on Reports of Squamous Cell Carcinoma in the Capsule Around Breast Implants
On March 8, the U.S. Food and Drug Administration (FDA) provided an update on reports of squamous cell carcinoma (SCC) in the scar tissue, or capsule, that forms around breast implants. Previously, on September 8, 2022, the FDA released a safety communication informing the public of reports of...
Pelabresib Plus Ruxolitinib in Patients With Myelofibrosis and No Prior JAK Inhibitor Treatment
In the phase II MANIFEST trial, reported in the Journal of Clinical Oncology, John Mascarenhas, MD, and colleagues found that the combination of the bromodomain and extraterminal domain inhibitor pelabresib and ruxolitinib was active in patients with myelofibrosis who had received no prior Janus...
Digital Rectal Examination Fails to Detect Early Prostate Cancer, Study Shows
A common method of detecting prostate cancer may not be accurate enough to serve as a reliable screening tool by itself, researchers have warned. The digital rectal exam (DRE), in which health-care providers check the prostate gland with a finger for unusual swelling or lumps in the rectum, is...
Cancer Mortality Decreased 33% in Newest Data Reported by the American Cancer Society
Overall cancer mortality rates have decreased 33% since 1991, and cervical cancer incidence decreased 65% from 2012 through 2019, according to the latest statistics reported by the American Cancer Society (ACS).1 Amid this good news, however, was a troubling 3% annual increase in prostate cancer...
Novel Herbal Oncology Program for Management of Cancer Symptoms at an NCI-Designated Cancer Center
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. In this installment, Jun J. Mao, MD, MSCE, Guest Editor of the Integrative Oncology series, and Yen ...
Highlights of the 2022 Annual Conference of the International Society of Geriatric Oncology
The 2022 Annual Conference of the International Society of Geriatric Oncology (SIOG) was held in Geneva, Switzerland, on October 28–30, 2022. The meeting was held in conjunction with the SIOG 2022 Public Policy Meeting: Global Policy to Action on Cancer in the Aging Population at UN Headquarters...
Nicotinamide for Chemoprevention of Skin Cancer in Solid Organ Transplant Recipients
In an Australian phase III trial (ONTRANS) reported in The New England Journal of Medicine, Allen et al found that 1 year of treatment with nicotinamide (vitamin B3) vs placebo did not reduce the risk of keratinocyte cancers or actinic keratoses in immunosuppressed solid organ transplant...
Understanding the Link Between Prognostic Perception and Patient-Oncologist Prognostic Discordance in the Advanced Cancer Setting
Studies have shown that although patients with advanced cancer want their oncologists to give them an honest assessment of their prognosis, most patients still perceive their illness as curable.1 And that lack of understanding of their prognosis can lead to reduced use of hospice care and increased ...
Nivolumab Followed by Nivolumab/Ipilimumab Boosting in Nonresponders Among Previously Treated Patients With Advanced Urothelial Carcinoma
In a German-Austrian phase II study (TITAN-TCC) reported in The Lancet Oncology, Grimm et al found that a strategy of nivolumab monotherapy followed by immunotherapeutic boosting including high-dose ipilimumab in nivolumab nonresponders showed activity in patients with unresectable or metastatic...
Early Intervention for Steroid-Refractory Chronic Graft-vs-Host Disease
This is Part 2 of Clinical Considerations in Chronic Graft-vs-Host Disease, a two-part video roundtable series. In this video, Dr. Yi-Bin Chen and Dr. Mitchell E. Horwitz discuss the case of a 65-year-old woman with inversion 16 acute myeloid leukemia who is in second complete remission. She...
Studies Focusing on Age- and Race-Related Disparities in Multiple Myeloma and Sickle Cell Disease
Research that addresses the compounding effects of age and race/ethnicity on access to quality health care and patient-centered outcomes such as physical function, frailty, and survival continues to be an emerging area of inquiry in hematology. Accordingly, novel research employing qualitative and...
First-Line Pembrolizumab in Older Patients With dMMR Metastatic Colorectal Cancer
In a retrospective cohort study reported in JAMA Network Open, Saberzadeh-Ardestani et al found that first-line pembrolizumab was associated with clinically significant prolongation of survival outcomes in mostly older patients with mismatch repair–deficient (dMMR) metastatic colorectal cancer....
Combination Chemotherapy May Be Safe and Effective Alternative for the Treatment of Patients With Non–Muscle-Invasive Bladder Cancer Amid BCG Shortage
Researchers have found that a safe, inexpensive chemotherapy combination may be better tolerated and more effective at preventing high-grade recurrence in patients with non–muscle-invasive bladder cancer than the standard-of-care bacillus Calmette-Guérin (BCG), according to a novel study published...
Have We Reached the Limits of Chemotherapy for Burkitt Lymphoma?
Burkitt lymphoma (BL) is a fascinating disease from which many groundbreaking medical and oncologic lessons have been learned. Since the Irish surgeon Denis P. Burkitt, MD, FRCS, FRS, first described rapidly enlarging jaw and facial tumors in Ugandan children in 1958,1 the study of BL has led to...
Triplet and Quadruplet Regimens in Smoldering Multiple Myeloma
Combination regimens beyond lenalidomide/dexamethasone were shown to significantly delay—and potentially prevent altogether—progression from smoldering disease to active multiple myeloma, according to researchers who reported findings from two studies at the 2022 American Society of Hematology...
Addition of Avelumab to Carboplatin/Paclitaxel in First-Line Treatment of Advanced or Recurrent Endometrial Cancer
As reported in The Lancet Oncology by Sandro Pignata, MD, and colleagues, the Italian phase II MITO END-3 trial showed no progression-free survival benefit with the addition of first-line avelumab to carboplatin/paclitaxel in patients with advanced or recurrent endometrial cancer. A trend toward...
Brexucabtagene Autoleucel in Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice
In an analysis from the U.S. Lymphoma CAR T Consortium reported in the Journal of Clinical Oncology, Wang et al found that standard-of-care treatment with brexucabtagene autoleucel in relapsed or refractory mantle cell lymphoma since its approval in this setting has been associated with response...
Camrelizumab/Apatinib in Recurrent or Metastatic Nasopharyngeal Carcinoma
In a Chinese phase II trial reported in the Journal of Clinical Oncology, Ding et al found that camrelizumab plus apatinib produced durable objective responses in most patients with recurrent or metastatic nasopharyngeal carcinoma. Study Details The multicenter trial enrolled 58 patients between...
Study Shows Activity of Talquetamab in Highly Refractory Multiple Myeloma
In the phase I/II MonumenTAL-1 trial, the novel bispecific antibody talquetamab produced responses in more than 70% of heavily pretreated patients with multiple myeloma.1 Of note, the safety profile confirmed results of the phase I portion of the study (recently published in TheNew England Journal...
Complete Response to Glofitamab at End of Treatment Heralds Prolonged Remission in Lymphoma
Patients with large B-cell lymphoma who achieve a complete response to glofitamab are very likely to remain in remission 12 months after the end of treatment, according to Martin Hutchings, MD, PhD, of Rigshospitalet in Copenhagen, who reported these findings at the 2022 American Society of...
